Baird downgraded Maravai Lifesciences (MRVI) to Neutral from Outperform with a price target of $3, down from $9, after the company announced ...
Shares of Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences") plunged over 21% in intraday trading on Tuesday, February 25, 2025, after the company disclosed it would be delaying its 2024 ...
Law Offices of Howard G. Smith announces an investigation on behalf of Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") investors concerning the Company's possible violations of ...
In a report released today, Matt Larew from William Blair maintained a Hold rating on Maravai Lifesciences Holdings (MRVI – Research Report).
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) stock fell 15% after the company announced it is postponing its fourth quarter and full year 2024 earnings release and conference call. The life ...
Maravai LifeSciences (MRVI) shares drop 15% premarket as it postpones 2024 earnings release, citing year-end financial review.
Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to ...
Maravai LifeSciences Holdings (NASDAQ:MRVI) is scheduled to announce Q4 earnings results on Tuesday, February 25th, after market close. The consensus EPS Estimate is -$0.04 (+95.0% Y/Y) and the ...
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has completed its previously announced ...
DENTSPLY SIRONA Inc. XRAY is scheduled to release fourth-quarter 2024 results on Feb. 27, before the opening bell. Stay up-to ...